Business Field
A global supply and solution provider focused on the pharmaceutical industry
Product
Technical Service
API
Excipients
Packaging Solution
Plant Extract
Laboratory Testing Equipment
Dossier
Oversea Techinical Supports
About Us
Always adhere to the service philosophy of "professionalism, efficiency, and reliability"
Xi'an Xinghui Material Technology Co.,ltd Established in 2021, headquartered in the historic ancient capital of Xi'an, with a branch office in the highly developed city-state of Singapore, we are a global pharmaceutical supplier and solutions provider. Leveraging our global supply chain as the core link, we are dedicated to offering integrated product supply and professional services to pharmaceutical enterprises, biotech companies, R&D institutions, and health product manufacturers. We serve as a bridge connecting high-quality international resources with localized needs.
Qualifications Certificates
A global supply and solution provider focused on the pharmaceutical industry
News
-
22-24th.April.2025 -
The EU's Key Medicines Act has entered the implementation phase, requiring the establishment of minimum inventories for key medicines and an increase in the local production ratio of active pharmaceutical ingredients (APIs). The United States continues to support domestic biomanufacturing through tools such as the Defense Production Act.
-
In vivo gene editing therapies from companies like Intellia/Regeneron and Verve Therapeutics (targeting conditions such as ATTR amyloidosis and hypercholesterolemia) have released longer-term positive data, validating the safety and efficacy of the technology and offering hope for "one-time cures" for common diseases. Related therapies from domestic companies like Boya Jiyin have also entered Phase II clinical trials.
-
The application of AI in target discovery, molecular generation, and clinical trial design is transitioning from experimentation to scale, exemplified by collaborations such as the NVIDIA/Lilly AI drug discovery alliance and the commercialization of Google DeepMind's AlphaFold 3. The market anticipates that the first new drugs fully designed and optimized by AI will enter critical clinical stages within the next 2-3 years.
